The risks and opportunities for pharma under China's new wave of regulations
This article was originally published in SRA
Executive Summary
Sweeping regulatory changes in China will have big implications for the pharmaceutical industry, Shanghai-based Ropes & Gray lawyer Katherine Wang tells Neena Brizmohun.